| Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity B Majumder, U Baraneedharan, S Thiyagarajan, P Radhakrishnan, ... Nature communications 6 (1), 6169, 2015 | 329 | 2015 |
| Screening and GC-MS profiling of ethanolic extract of Tylophora pauciflora T Starlin, PS Prabha, BKA Thayakumar, VK Gopalakrishnan Bioinformation 15 (6), 425, 2019 | 54 | 2019 |
| Evaluation of maize grain and polyunsaturated fatty acid (PUFA) as energy sources for breeding rams based on hormonal, sperm functional parameters and fertility S Selvaraju, P Raju, SBN Rao, S Raghavendra, S Nandi, D Dineshkumar, ... Reproduction, Fertility and Development 24 (5), 669-678, 2012 | 33 | 2012 |
| Inhibition of rapamycin-induced AKT activation elicits differential antitumor response in head and neck cancers P Radhakrishnan, U Baraneedharan, S Veluchamy, M Dhandapani, ... Cancer research 73 (3), 1118-1127, 2013 | 27 | 2013 |
| Effect of detoxified karanja (Pongamia spp.) cake on testicular architecture and semen production in ram lambs D Dineshkumar, S Selvaraju, S Parthipan, A Thayakumar, D Rajendran, ... animal 7 (10), 1697-1703, 2013 | 20 | 2013 |
| Nanoengineered disruption of heat shock protein 90 targets drug-induced resistance and relieves natural killer cell suppression in breast cancer M Smalley, SK Natarajan, J Mondal, D Best, D Goldman, B Shanthappa, ... Cancer research 80 (23), 5355-5366, 2020 | 14 | 2020 |
| Transcriptional antagonism by CDK8 inhibition improves therapeutic efficacy of MEK inhibitors CF Malone, M Kim, G Alexe, K Engel, AB Forman, A Robichaud, ... Cancer research 83 (2), 285-300, 2023 | 7 | 2023 |
| Predicting tumor-immune response to checkpoint inhibitors using a novel patient-derived live tumor explant model. P Radhakrishnan, A Goldman, B Ulaganathan, A Thaya Kumar, ... Journal of Clinical Oncology 35 (15_suppl), e20035-e20035, 2017 | 4 | 2017 |
| Nonuniform T-cell infiltration induced by PD-1 checkpoint blockade, ex vivo, predicts distinct clinical response M Smalley, B Shanthappa, H Gertje, M Lawson, B Ulaganathan, ... Cancer Research 78 (13_Supplement), 705-705, 2018 | 1 | 2018 |
| Abstract LB-346: Case study: Non-uniform response to therapy in multiple metastatic is predicted using CANscriptTM, a live tissue, ex-vivo, platform C Ikpeazu, M Smalley, B Ulaganathan, A Thayakumar, L Majeiko, ... Cancer Research 78 (13_Supplement), LB-346-LB-346, 2018 | 1 | 2018 |
| Profiling metastatic lesions from a pembro-refractory patient to reveal distinct genomic instabilities and non-uniform response to drug combinations, ex vivo. C Ikpeazu, M Smalley, B Ulaganathan, A Thayakumar, S Basavaraja, ... Journal of Clinical Oncology 36 (15_suppl), e18021-e18021, 2018 | 1 | 2018 |
| A live tissue platform allows dynamic measurement of neovascularization and prediction of clinical response in human breast cancer samples, ex vivo M Smalleye, N Alam, N Murmu, SP Somashekhar, B Ulaganathan, ... SABCS, 2018 | 1 | 2018 |
| Therapy-induced priming of natural killer cells predicts patient-specific tumor rejection in multiple breast cancer indications M Smalley, B Shanthappa, H Gertje, M Lawson, B Ulaganathan, ... Annals of Oncology 28, xi9, 2017 | 1 | 2017 |
| Characterizing immunotherapy-induced lymphocyte infiltration at the single patient level using CANscriptTM, an ex-vivo human tumor model M Smalleyc, BU Shanthappa, H Gertje, M Lawson, B Ulaganathan, ... Immunotherapy of cancer 5, 2017 | 1 | 2017 |
| Identification of responders for Anti-CTLA4 in refractory colorectal cancers using CANScript™ platform B Majumder, B Ulaganathan, A Thayakumar, S Thiyagarajan, N Brijwani, ... Cancer Research 75 (15_Supplement), 1304-1304, 2015 | 1 | 2015 |
| Human tumor derived Oncoprint® platform predicts molecular mechanism of sensitivity and resistance to Fragmin in pancreatic cancer. M Sundaram, S Thiyagarajan, M Dhandapani, N Brijwani, A Prasath, ... Cancer Research 73 (8_Supplement), 5072-5072, 2013 | 1 | 2013 |
| PAT-1102, a novel HDAC inhibitor exhibits potent anti-tumor efficacy in patient-derived refractory solid tumors. P Radhakrishnan, M Dhandapani, B Ulaganathan, A Thayakumar, ... Cancer Research 73 (8_Supplement), 2051-2051, 2013 | 1 | 2013 |
| Abstract P6-07-03: A live tissue platform allows dynamic measurement of neovascularization and prediction of clinical response in human breast cancer samples, ex vivo M Smalley, N Alam, N Murmu, S Somashekhar, B Ulaganathan, ... Cancer Research 79 (4_Supplement), P6-07-03-P6-07-03, 2019 | | 2019 |
| Clinical-stage monitoring of adaptive tumor resistance to PD-1 checkpoint blockade M Smalley, B Shanthappa, H Gertje, M Lawson, B Ulaganathan, ... EUROPEAN JOURNAL OF CANCER 103, E4-E5, 2018 | | 2018 |
| Abstract P5-11-04: Therapy-induced priming of natural killer cells predicts patient-specific tumor rejection in multiple breast cancer indications M Smalley, BU Shanthappa, H Gertje, M Lawson, B Ulaganathan, ... Cancer Research 78 (4_Supplement), P5-11-04-P5-11-04, 2018 | | 2018 |
Baraneedharan UlaganathanFounder, Rident Biosciences在 ridentbio.com 的电子邮件经过验证
